Erratum: A randomized phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: Japan Clinical Oncology Group Study (JCOG1607, HERB TEA study) (Japanese Journal of Clinical Oncology DOI: 10.1093/jjco/hyab101)

Akihiko Shimomura, Kenji Tamura, Kiyo Tanaka, Tomonori Mizutani, Keita Sasaki, Yuta Sekino, Masataka Sawaki, Tadahiko Shien, Taro Shibata, Hiroji Iwata

Research output: Contribution to journalComment/debatepeer-review

Abstract

In the originally published version of this manuscript, the title and a citation was incorrect. In the title, the spelling of the author group was incorrect. It should read “Japan Clinical Oncology Group Study”, instead of, “Japan Clinical Oncollgy Group Study”. The author of reference number 3 was incorrect. It should read “Ministry of Health, Labour and Welfare", instead of, "Ministry of Health Law”. These errors have been corrected online.

Original languageEnglish
Pages (from-to)1479
Number of pages1
JournalJapanese journal of clinical oncology
Volume51
Issue number9
DOIs
Publication statusPublished - Sep 1 2021

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint

Dive into the research topics of 'Erratum: A randomized phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: Japan Clinical Oncology Group Study (JCOG1607, HERB TEA study) (Japanese Journal of Clinical Oncology DOI: 10.1093/jjco/hyab101)'. Together they form a unique fingerprint.

Cite this